News

Proteomics & Metabolomics | Paradigm4 Launches REVEAL: Multi-Omics App for Advanced Cross-Study Analyses

Paradigm4 has launched its REVEAL™: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.

whitepages icon x

Biocompare || Peptidomics: Methods in the search for molecular disease signatures

Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.

whitepages icon x

GEN: Genetic Engineering and Biotechnology News | The Vast Potential of Single-Cell Analysis

Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk

whitepages icon x

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified